Makoto Saegusa

Prof. Dr. Makoto Saegusa


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 January 2001 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MSMakoto Saegusa
Makoto Saegusa
MHM Hashimura
M Hashimura
TYT Yoshida
T Yoshida
IOI Okayasu
I Okayasu
To clarify the possible role of aberrant β-catenin expression during endometrial tumorigenesis, a total of 199 cases of endometrial carcinomas (endometrioid type), as well as 37 cases of simple/complex and 32 of atypical hyperplasias, was consecutively investigated for immunohistochemistry, along with 141 normal endometrial samples distant from carcinomas. Of 199 carcinoma cases, 73 tumours as well as 44 normal samples were also analysed using a combination of RT-PCR and Southern blot hybridization, Western blot, and mutation gene assays. Cell membrane β-catenin immunoreactivity showed a stepwise decrease from normal, through atypical hyperplasia, to grade 3 carcinomas. In contrast, the nuclear accumulation in atypical hyperplasias and grade 1 or 2 tumours was higher than in simple/complex hyperplasias. Mutations in exon 3 of the β-catenin gene involving codons 33, 34, 37, 41, and 45 were observed in 16 (22.9%) of 70 endometrial carcinomas, as well as 3 (12.5%) of 24 atypical hyperplasias, the results being significantly related to low membrane and high nuclear immunoreactivity but not relative mRNA expression levels, suggesting that the gene mutations may be closely associated with changes in subcellular distribution. In addition to significant association between β-catenin mutation and low grade histological malignancy (P=0.048), the mutations were detected in none of 15 and 13 (26%) of 50 tumours with or without lymph node metastasis, the difference being significant (P=0.027). These findings suggest that β-catenin abnormalities may play an important role in a relatively early event during the endometrial hyperplasia-carcinoma sequence. © 2001 Cancer Research Campaign http://www.bjcancer.com

1 June 2009 in The American Journal of Pathology
Verified
Journal Article
Closed access
MSMakoto Saegusa
Makoto Saegusa
MHMiki Hashimura
Miki Hashimura
TKTakeshi Kuwata
Takeshi Kuwata
IOIsao Okayasu
Isao Okayasu

1 May 2004 in The American Journal of Pathology
Verified
Journal Article
Closed access
MSMakoto Saegusa
Makoto Saegusa
MHMiki Hashimura
Miki Hashimura
TKTakeshi Kuwata
Takeshi Kuwata
MHMieko Hamano
Mieko Hamano
IOIsao Okayasu
Isao Okayasu

1 September 2015 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
TMToshihide Matsumoto
Toshihide Matsumoto
MYMasaaki Yamazaki
Masaaki Yamazaki
HTHiroyuki Takahashi
Hiroyuki Takahashi
SKSabine Kajita
Sabine Kajita
ESErina Suzuki
Erina Suzuki
MSMakoto Saegusa
Makoto Saegusa
Objectives. We focused on the differences in molecular mechanisms in the early stages of endometriosis-associated ovarian endometrioid carcinoma (OEMCa

1 August 2012 in The American Journal of Pathology
Verified
Journal Article
Closed access
MSMakoto Saegusa
Makoto Saegusa
MHMiki Hashimura
Miki Hashimura
ESErina Suzuki
Erina Suzuki
TYTsutomu Yoshida
Tsutomu Yoshida
TKTakeshi Kuwata
Takeshi Kuwata